DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter Phase 1, dose-escalation study of the selective GCN2 activator DCC-2812 given as monotherapy to patients with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer. The trial focuses on characterizing safety, tolerability, pharmacokinetics, and any preliminary anti-tumor activity. Key eligibility features include the ability to take oral medication, adequate organ function, and no recent anticancer or investigational therapies or recent major surgery. Participants will be treated at specialized oncology centers with scheduled clinic visits for dosing, monitoring, and imaging.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
* Able to take oral medication
* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
* Adequate organ function and electrolytes

Key Exclusion Criteria:

* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
* Impaired cardiac function
* Major surgery within 28 days of the first dose of study drug

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting
• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting
• Cleveland Clinic
  Cleveland, Ohio, United States Recruiting
• Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States Recruiting
• Vanderbilt- Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Clinical Team
• Email: clinicaltrials@deciphera.com
• Phone: 888-724-3274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Investigating QXL138AM for patients with advanced solid tumors and multiple myeloma

  This study is testing a new drug called QXL138AM to see if it can safely help people with advanced solid tumors and multiple myeloma.

  Recruiting at 11 sites Phase 1 Nammi Therapeutics Inc · Los Angeles, California and 10 other locations · NCT06582017

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Combining local therapies with systemic treatment for certain cancers

  This study is testing if adding local treatments like targeted radiation or ablation can help people with certain types of cancer, such as prostate or kidney cancer, stay on their main treatment longer without needing changes.

  Recruiting University of California, Davis · Sacramento, California · NCT06101290

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.